{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T02:50:33Z","timestamp":1763088633142,"version":"3.45.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Chirurgie Plastique Esth\u00e9tique"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.anplas.2025.06.017","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:40:01Z","timestamp":1762962001000},"page":"500-510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Examen anatomopathologique en canc\u00e9rologie mammaire\u00a0: tour d\u2019horizon des types histologiques, modalit\u00e9s de l\u2019examen, biomarqueurs pr\u00e9dictifs et innovants"],"prefix":"10.1016","volume":"70","author":[{"given":"V.","family":"Cockenpot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"Breast tumours","author":"WHO Classification of Tumours Editorial Board","key":"10.1016\/j.anplas.2025.06.017_bib0120"},{"issue":"15","key":"10.1016\/j.anplas.2025.06.017_bib0125","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.3390\/cancers13153695","article-title":"Lobular breast cancer: histomorphology and different concepts of a special spectrum of tumors","volume":"13","author":"Christgen","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.anplas.2025.06.017_bib0130","doi-asserted-by":"crossref","first-page":"100463","DOI":"10.1016\/j.modpat.2024.100463","article-title":"Molecular and clinical portrait of HER2-low invasive lobular carcinomas","volume":"37","author":"Djerroudi","year":"2024","journal-title":"Modern Pathol"},{"issue":"6","key":"10.1016\/j.anplas.2025.06.017_bib0135","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annpat.2021.07.014","article-title":"Mise \u00e0 jour 2021\u00a0des recommandations du GEFPICS pour l\u2019\u00e9valuation du statut HER2\u00a0dans les cancers infiltrants du sein en France","volume":"41","author":"Franchet","year":"2021","journal-title":"Ann Pathol"},{"issue":"6","key":"10.1016\/j.anplas.2025.06.017_bib0140","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.annpat.2019.04.004","article-title":"Recommandations du GEFPICS pour la prise en charge des pr\u00e9l\u00e8vements dans le cadre du traitement n\u00e9oadjuvant du cancer du sein","volume":"39","author":"Maran-Gonzalez","year":"2019","journal-title":"Ann Pathol"},{"issue":"12","key":"10.1016\/j.anplas.2025.06.017_bib0145","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.anplas.2025.06.017_bib0150","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"key":"10.1016\/j.anplas.2025.06.017_bib0155","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Fraser Symmans","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.anplas.2025.06.017_bib0160","doi-asserted-by":"crossref","first-page":"993","DOI":"10.5858\/arpa.2023-0950-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-CAP guideline update","volume":"147","author":"Wolff","year":"2023","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"10.1016\/j.anplas.2025.06.017_bib0165","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67\u00a0in breast cancer: updated recommendations from the International Ki67\u00a0in Breast Cancer Working Group","volume":"113","author":"Nielsen","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.anplas.2025.06.017_bib0170","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anplas.2025.06.017_bib0175","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.anplas.2025.06.017_bib0180","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to guide chemotherapy benefit in node\u00a0\u2013\u00a0positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"year":"2023","series-title":"Actualisation 2023\u00a0: utilit\u00e9 clinique des signatures g\u00e9nomiques dans le cancer du sein RH+\/HER2\u2013 de stade pr\u00e9coce. Rapport d\u2019\u00e9valuation technologique adopt\u00e9 par d\u00e9cision no\u00a02023. 0383\/DC\/SEAP du 19\u00a0octobre 2023","author":"Haute Autorit\u00e9 de sant\u00e9 (HAS)","key":"10.1016\/j.anplas.2025.06.017_bib0185"},{"issue":"20","key":"10.1016\/j.anplas.2025.06.017_bib0190","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.anplas.2025.06.017_bib0195","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1\u00a0mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3\u00a0trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.anplas.2025.06.017_bib0200","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1053\/j.semdp.2022.06.015","article-title":"Update on prognostic and predictive biomarkers of breast cancer","volume":"39","author":"Hou","year":"2022","journal-title":"Semin Diagn Pathol"},{"issue":"3","key":"10.1016\/j.anplas.2025.06.017_bib0205","first-page":"217","article-title":"Pembrolizumab plus chemotherapy for previously untreated, PD-L1\u00a0\u2013\u00a0positive (CPS\u00a0\u2265\u00a010) locally recurrent unresectable or metastatic triple-negative breast cancer (KEYNOTE-355): overall survival results from a randomised, double-blind, phase 3\u00a0trial","volume":"387","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.anplas.2025.06.017_bib0210","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s11912-024-01560-3","article-title":"Screening and testing for homologous recombination repair deficiency (HRD) in breast cancer: an overview of the current global landscape","volume":"26","author":"Daly","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"13","key":"10.1016\/j.anplas.2025.06.017_bib0215","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.anplas.2025.06.017_bib0220","first-page":"155","article-title":"Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications","volume":"19","author":"Croessmann","year":"2021","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.anplas.2025.06.017_bib0225","doi-asserted-by":"crossref","first-page":"e2026921","DOI":"10.1001\/jamanetworkopen.2020.26921","article-title":"Association of circulating tumor dna with disease-free survival in breast cancer","volume":"3","author":"Cullinane","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.anplas.2025.06.017_bib0115","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","article-title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","volume":"21","author":"Turner","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Annales de Chirurgie Plastique Esth\u00e9tique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0294126025001165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0294126025001165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T02:46:31Z","timestamp":1763088391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0294126025001165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0294126025001165"],"URL":"https:\/\/doi.org\/10.1016\/j.anplas.2025.06.017","relation":{},"ISSN":["0294-1260"],"issn-type":[{"type":"print","value":"0294-1260"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Examen anatomopathologique en canc\u00e9rologie mammaire\u00a0: tour d\u2019horizon des types histologiques, modalit\u00e9s de l\u2019examen, biomarqueurs pr\u00e9dictifs et innovants","name":"articletitle","label":"Article Title"},{"value":"Annales de Chirurgie Plastique Esth\u00e9tique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anplas.2025.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}